According to the Zhitong Finance App, McPharmaceutical-B (02335.HK) issued an announcement. The research results on XTL6001, one of the Group's main products, have been accepted for presentation at several top internationally recognized academic conferences in the fields of diabetes, metabolic diseases and kidney disease. Following the ADA's initial report, further analysis will be presented at upcoming EASD and ASN annual meetings.

According to the Zhitong Finance App, McPharmaceutical-B (02335.HK) issued an announcement. The research results on XTL6001, one of the Group's main products, have been accepted for presentation at several top internationally recognized academic conferences in the fields of diabetes, metabolic diseases and kidney disease. Following the ADA's initial report, further analysis will be presented at upcoming EASD and ASN annual meetings.